Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR), intercalated therapy has not been properly evaluated. In a phase II trial, 38 pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Zwitter, Matjaz, Rajer, Mirjana, Stanic, Karmen, Vrankar, Martina, Doma, Andrej, Cuderman, Anka, Grmek, Marko, Kern, Izidor, Kovac, Viljem
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074447/
https://ncbi.nlm.nih.gov/pubmed/27261103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1195049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados